Overview

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

Status:
Completed

Trial end date:
2020-06-26

Target enrollment:

Participant gender:

Summary

The primary objective of this study was to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Antiviral Agents
Remdesivir